Table 2. Comparison of receiver operating characteristic (ROC)–areas under the curve for testosterone and the candidate biomarkers in relation to the prediction of hypogonadism and its sequelae in patients.

Analyte	Low T		Low T*		Low cFT		IR		DM		LBD		CVRLP		MetS
	(T ≤ 8 nmol/l)		(T ≤ 8 nmol/l)		(cFT <220 pmol/l)		(HOMA-IR >2.5)		-		(z-score <−1)		(ApoB/ApoA1 ≥0.9)
	AUC (Sp,Se)	p	AUC (Sp,Se)	p	AUC (Sp,Se)	p	AUC (Sp,Se)	p	AUC (Sp,Se)	p	AUC (Sp,Se)	p	AUC (Sp,Se)	p	AUC (Sp,Se)	p
4HPPD	0.75(85,59)	8.38E−04	0.77(86,59)	2.66E−04	0.69(83,57)	5.14E−03	0.79(84,70)	1.20E−04	0.89(93,75)	9.00E−03	0.64(76,61)	2.24E−02	0.74(46,90)	5.79E−03	0.74(95,50)	5.31E−03
ALDOB	0.69(68,73)	8.25E−03	0.70(67,73)	5.39E−03	0.66(67,71)	1.56E−02	0.73(71,75)	2.85E−03	0.85(63,100)	1.80E−02	0.57(98,27)	1.93E−01	0.71(83,55)	4.64E−02	0.74(82,64)	6.02E−03
IGFBP6	0.69(77,59)	1.05E−02	0.70(81,59)	4.89E−03	0.63(44,81)	7.24E−02	0.57(42,80)	3.50E−01	0.59(39,100)	5.40E−01	0.63(43,78)	2.75E−01	0.59(48,80)	1.87E−01	0.65(45,93)	8.45E−02
Testosterone	-	-	-	-	-	-	0.71(76,70)	4.96E−03	0.55(32,100)	7.24E−01	0.75(74,74)	5.12E−04	0.66(65,85)	6.55E−03	0.56(72,57)	5.08E−01
MMA	0.79(74,82)	9.23E−05	0.80(72,86)	3.86E −05	0.70(69,71)	3.90E−03	0.79(82,70)	1.46E−04	0.92(84,100)	5.00E−03	0.78(82,65)	1.40E−02	0.75(73,75)	3.65E−03	0.78(63,86)	1.57E−03

Significant p values are highlighted in bold and underlined. *Excluding patients with testosterone values from the borderline low testosterone (8 < BL_T ≤ 12).

cFT: calculated free testosterone; IR: insulin resistance; DM: diabetes mellitus type 2; LBD: low bone density; CVRLP: cardiovascular risk lipid profile ;MetS: metabolic syndrome; AUC:area under the curve; Spe: specificity in %; Se: sensitivity in %.